Pre-order Enquiry
Request Free Sample
Global Quetiapine Fumarate Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
SKU ID : GIR-13837009 | Publishing Date : 08-Feb-2019 | No. of pages : 120
Request Sample
Request Customization
Check Discounts
Quetiapine Fumarate is an atypical antipsychotic drug used to treat psychiatric disorders such as schizophrenia, bipolar disorder and depression. It may be used alone or in combination with other psychiatric medications. It is taken orally, and is available only by prescription, under the supervision of a medical practitioner.
Scope of the Report:
The Quetiapine Fumarate was developed by AstraZeneca from 1992 to 1996. It was first approved by the FDA in 1997.
The product is invented and first produced in the UK by AstraZeneca. AstraZeneca is also the leader of the Quetiapine Fumarate base drugs.
The Average gross of the industry is over 40%. However, since there are new companies coming into the area, the gross is declining in the last several years.
The worldwide market for Quetiapine Fumarate is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new study.
This report focuses on the Quetiapine Fumarate in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
AstraZeneca
Intas
TAPI
Accord
Hexal
Dr.Reddy's
Lupin
Sun Pharmaceutical
Hunan Dongting Pharm
SuZhou NO.4 Phamaceutical Factory
Fuan Pharmaceutical
Zhejiang Supor Pharmaceuticals
Zhejiang Huahai Pharmaceutical
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Immediate Release Tablets
Extended Release Tablets
Market Segment by Applications, can be divided into
Application I
Application II
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Quetiapine Fumarate product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Quetiapine Fumarate, with price, sales, revenue and global market share of Quetiapine Fumarate in 2017 and 2018.
Chapter 3, the Quetiapine Fumarate competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Quetiapine Fumarate breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Quetiapine Fumarate market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Quetiapine Fumarate sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Scope of the Report:
The Quetiapine Fumarate was developed by AstraZeneca from 1992 to 1996. It was first approved by the FDA in 1997.
The product is invented and first produced in the UK by AstraZeneca. AstraZeneca is also the leader of the Quetiapine Fumarate base drugs.
The Average gross of the industry is over 40%. However, since there are new companies coming into the area, the gross is declining in the last several years.
The worldwide market for Quetiapine Fumarate is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new study.
This report focuses on the Quetiapine Fumarate in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
AstraZeneca
Intas
TAPI
Accord
Hexal
Dr.Reddy's
Lupin
Sun Pharmaceutical
Hunan Dongting Pharm
SuZhou NO.4 Phamaceutical Factory
Fuan Pharmaceutical
Zhejiang Supor Pharmaceuticals
Zhejiang Huahai Pharmaceutical
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Immediate Release Tablets
Extended Release Tablets
Market Segment by Applications, can be divided into
Application I
Application II
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Quetiapine Fumarate product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Quetiapine Fumarate, with price, sales, revenue and global market share of Quetiapine Fumarate in 2017 and 2018.
Chapter 3, the Quetiapine Fumarate competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Quetiapine Fumarate breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Quetiapine Fumarate market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Quetiapine Fumarate sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
